The majority of healthcare firms rarely have profited after funding the research and development division despite having huge revenues. Today another such stock Monopar Therapeutics (NASDAQ: MNPR) rises by over 15% on more than a million shares due to partnering with Northstar and Aragen to test uPRIT drug on severe COVID-19.
Until the end of the trading day, MNPR may double in value because of the trending COVID-19 issue. There is no potential drug to stop the pandemic as clinical tests are not finished yet by many developers.
However, Russia’s officials claim that the drug for COVID-19 is ready to be distributed this fall. The statement of Putin, President of the Russian Federation made several biotech experts sceptic about the effectiveness and safety of the new vaccine.
Editor in Chief.
Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life